<SEC-DOCUMENT>0001104659-20-110494.txt : 20210216
<SEC-HEADER>0001104659-20-110494.hdr.sgml : 20210216
<ACCEPTANCE-DATETIME>20200930172558
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-20-110494
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MONOGRAM ORTHOPAEDICS INC
		CENTRAL INDEX KEY:			0001769759
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				812349540
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		53 BRIDGE STREET UNIT 507
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11201
		BUSINESS PHONE:		(718) 576-3205

	MAIL ADDRESS:	
		STREET 1:		53 BRIDGE STREET UNIT 507
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11201
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 30, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Celeste M. Murphy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Branch Chief</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Life Sciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington DC 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; width: 8%; padding-top: 0; padding-right: 0; font-weight: bold; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; width: 3%; padding-top: 0; padding-right: 0; font-weight: bold; text-indent: 0">Re:</TD>
    <TD STYLE="padding-bottom: 0; width: 89%; padding-top: 0; padding-right: 0; font-weight: bold; text-indent: 0">Monogram Orthopaedics, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-top: 0; padding-right: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-top: 0; padding-right: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-top: 0; padding-right: 0; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Offering Statement on Form 1-A</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Submitted August 28, 2020</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; padding-top: 0; padding-right: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-top: 0; padding-right: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-top: 0; padding-right: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>File No. 024-11305</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 43.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Ms. Murphy:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We acknowledge receipt of the comments in the letter dated September
24, 2020 from the staff of the Division of Corporate Finance (the &ldquo;Staff&rdquo;) the regarding the Offering Statement of
Monogram Orthopaedics, Inc. (the &ldquo;Company&rdquo;), which we have set out below, together with our responses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 291.3pt 0pt 7pt"><U>Form 1-A Submitted August 28, 2020</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 291.3pt 0pt 7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 291.3pt 0pt 7pt"><U>Summary,
page 4</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 291.3pt 0pt 7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt"><I>1.</I></TD><TD STYLE="padding-right: 6.2pt"><I>Please revise the Summary Overview to clarify that you have not yet made 501(k) premarket notification
submissions for any of your product candidates, and that such submission is required in order to obtain clearance to market your
products. Potential investors should be able to clearly ascertain from the Summary what stage of development the company is in
and what steps remain prior to commercialization.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">In response to the Staff&rsquo;s comment, the &ldquo;Summary
Overview&rdquo; of the Offering Statement has been revised to clarify that the Company has not yet made 501(k) premarket notification
submissions for any of its product candidates, and that such submission is required in order to obtain clearance to market your
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 5.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"><U>Jury Trial Waiver, page 19</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt"><I>2.</I></TD><TD STYLE="padding-right: 0.1in"><I>We note that the provision relating to an investor's waiver of a right to a jury trial applies
to federal securities law claims. Please revise your disclosure to clearly state that investors cannot waive compliance with federal
securities laws and the rules and regulations promulgated thereunder.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">In response to the Staff&rsquo;s comment, the disclosure
regarding the Jury Trial Waiver in the Offering Statement has been revised to clearly state that investors cannot waive compliance
with federal securities laws and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"><U>No Minimum Offering Amount, page 19</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt"><I>3.</I></TD><TD STYLE="padding-right: 17.55pt"><I>We note your statements on page 19 and elsewhere that there is no minimum offering amount
and that the company may close on any funds that it receives. However, we also note your statements on pages 1 and 7 that reference
a minimum amount of shares to be sold. Please revise these statements to avoid confusion and clarify the best-efforts offering
structure.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.55pt 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">In response to the Staff&rsquo;s comment, the
Offering Statement has been revised on the Cover Page and elsewhere to make clear that there is no minimum offering amount, and
to clarify that the offering being conducted on a &ldquo;best efforts&rdquo; basis means that there is no guarantee that any minimum
amount will be sold in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.55pt 0pt 5.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"><U>Use of Proceeds to Issuer, page 20</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt"><I>4.</I></TD><TD STYLE="padding-right: 8.85pt"><I>We note your statements under the Use of Proceeds discussion that the company intends to &quot;try
and fund&quot; the development of the Monogram total knee and robotic system with proceeds received. Please revise your discussion
to clarify at each capital raise level how far you anticipate the proceeds will go towards this goal (i.e., how much funding you
anticipate is required to develop the system) and how you will secure the remainder of the funding needed if there is an anticipated
shortfall.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">The statements in the &ldquo;Use of Proceeds&rdquo; section
of the Offering Statement have been revised as requested by the Staff.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"><U>Plan of Operations and Milestones, page 31</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt"><I>5.</I></TD><TD STYLE="padding-right: 15.5pt"><I>Please remove your statements on pages 31 and 32 regarding the years in which you expect to
receive FDA approval for your robotic system and implant, as such approval is not assured or within your control.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 15.5pt 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">In response to the Staff&rsquo;s comment, the Company has removed
the specific year references in the &ldquo;Plan of Operations and Milestones&rdquo; section regarding the years in which the Company
expects to receive FDA approval for its robotic system and implant. In an effort to comply with the disclosure requirements of
Item 9(c) of Part II of Form 1-A, the Company has instead replaced those references with the Company&rsquo;s estimates on how long
the FDA review process could take before receiving a determination from the FDA. We further clarify that such timelines are only
the Company&rsquo;s best reasonable estimates, and that there is no guarantee that, at the end of such review period, the Company&rsquo;s
products will receive any FDA approval whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7pt"><U>Interest of Management and Others in Certain Transactions,
page 36</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt"><I>6.</I></TD><TD STYLE="padding-right: 8.9pt"><I>We note your statement that payments under the License Agreement include: annual license maintenance
fees, milestone payments (upon completion of certain events, such as FDA Clearance of Monogram&rsquo;s custom implants), running
royalties (subject to certain adjustments) and sublicense fees. Please revise to disclose the material terms of the agreement,
including the aggregate potential milestone payments, the royalty rate to be paid, and the term and termination provisions.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.9pt 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.9pt 0pt 5.45pt"><I></I></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.9pt 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">In response to the Staff&rsquo;s comment, the
Company has revised the disclosure of the Licensing Agreement in the &ldquo;Interest of Management and Others in Certain Transactions&rdquo;
section of the Offering Statement to disclose the material terms of the agreement, including the aggregate potential milestone
payments, the royalty rate to be paid, the licensing and sublicensing fee provisions, and the term and termination provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.9pt 0pt 5.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5.45pt"></TD><TD STYLE="width: 35.35pt"><I>7.</I></TD><TD STYLE="padding-right: 5.5pt"><I>We note your disclosure that as part of the Licensing Agreement with Mount Sinai you are obligated
to enter into a stock purchase agreement for the shares of Common Stock already issued to Mount Sinai before September 22, 2019,
but have not yet done so. Please update your disclosure to reflect the current status of this agreement, as the date in question
has already passed.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">In response to the Staff&rsquo;s comment, the Company has filed
as Exhibit 6.15 to the Offering Statement the above-referenced Stock Purchase Agreement between the Company and Mount Sinai, and
has also updated the disclosure in the Offering Statement regarding the status of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you again for the opportunity to respond to your questions
to the Offering Statement of Monogram Orthopaedics, Inc. If you have additional questions or comments, please contact me at Andrewstephenson@crowdchecklaw.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6.2pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><I><U>/s/ Andrew Stephenson</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Andrew Stephenson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Partner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">CrowdCheck Law LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">cc: Benjamin Sexson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Monogram Orthopaedics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8.9pt 0pt 5.45pt"><I>&nbsp;</I></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> -P# 2(  A$! Q$!_\0
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M/$OBS2/"5K#<ZQ.\44SF-"D3/D@9[#TK0L-4LM35VLKA9E0X8J#@&O+?C_\
M\BWI/_7VW_H!KJI6FUKHSCJ<T$[JS1ZU%*D\*2H<HZAE/L>:?64-3L=(\/6U
MWJ-W#:VZ0)F25PH^Z./<^U8]G\3O!M_>K:0:[!YKMM7S%9%)_P!Y@!1RM[(.
M9=3K:*Q]3\5:'HVHV^GZCJ4-M=7&#%')D%\G:,'&.O%6=8UO3= LA>:K>1VE
MN7""23.-QZ#CZ&E9A=%^BJ>G:K8ZOIL>H6%U'<6<@)29#\IP2#^H-8<?Q%\)
M3 M%K<$@!P2BN1G\!19A=%'P1IUMK-E)XGU&&.YO[^5V5I0'\F,,0J+GH !6
MY-H.EV)U'4;2SC@NIK5HY&C^4, ">5'&??&:Y74=0NOAH\[K'%>Z)=3M+#!O
M*2V[L<LHX(*YK3\/Z[J?BG3;_4GCMK?3'@:." $M+NP<LS8 Q[ 5K)2^);'/
M"45[C7O?UJ5_AMH6GKX0T_4);:.:\GCW&:50S* 2%52>@  X%.\(V%MKUSJ/
MB/4H4N;N2[E@@$J[A!$C;0J@]#QDFM3P%"UMX&TF%R"R0X.WI]XUA:M=77PZ
MN+O4+=(KO1KV8S-:LQ22&4_>*'!!4]<&FVY2DEN))0A%M:+?[MRSXUT^VT6"
MW\2Z;#':WUG/&',0"">-F"LC =>M6)E_LGXGP3#B#6;,Q-Z>=%R/QVDBLK3;
MZZ^)4EO-)'%9Z):3K+);[R\L\B\J&.  H/-;7C^VG?P^FH6;HE[IUPES [],
MYVD?B&HV:@]PT:=2.VC_ ,SF-1>675[WQO&6,6F:@EJ@!X:V7Y)3_P!],3_P
M&NDU(KJ_Q T:S4AX-/@?4),'C<WR1_U-:.DZ#!!X.@T64"2-[4QS'^^7&6/X
MDDUB?#O3KJ"'4;N_F2:Y\Q;-77/^KA7:O7UR32<E9OMH"@TTGUU?]?=]P[P[
MI\&OZYK&N:I&EU+!>26=I'*-RP1IQP#P"3R34/Q&\-:?+X6OM2MX([:\MHBW
MFQ )YB?Q(V.H/OWQ2:U)=^ [Z^UNT6*YTJ^D$ES:.Q5TEZ%D.".>X-86K^(-
M3\?>%-1>S2'3]-MTS*CN7EF8$87@8"YY[GBJBI.2DMB9.*BZ;7O:_P##FSXL
MN)9+/1--5]D4T2,_N?E S],YKH#X,T0VJ0&V.5()E#'>WKD^]1:OX>&M:#9A
M9%CN8(E*.>A^49!]N*Y>'7_$,LZ:4E[&)%8*)"O)QZG'/Y5XM9PIUI.K&_-M
MU^1]+AU.MAH1H3Y7&_-T^?F6_%UG$_B72[) (X6BCB 3C:I<CBI?&6@:=INC
MPSV=N(7641G:3\P(/7WXJ;7[6YE\4Z/)(T1=%B\S;D G?SCVK2\<0/<:"B(5
M!\]3\Q]C43I)QK-K7I]R-*5>498:*EIU^]F/XHO[@>$M(A#M_I4:F5O[P"CC
M\S^E5/MVE?V9]C'AFZSLV^;L^?./O9QFNDGT%=9\)V-HSA)XX4:.3J VW'Y&
MN9?Q+KUI_P 2@S0&5?W8GVDMZ=?ZXJ:R<)\TWHTDM$^FVNQ>&<:E/DIK6,FW
MJX]='IN6-'U"^L/!6J*5EC>!@(F92"H? .,^G)_&KOA3PUIMWHJ7EY"MQ+.6
M^\3A1G'Y\=:W[33;B?P_]@U:Y^TO(A5W QP>G/<CUKB9[C6/!L[V,-W%)"YW
M*"F<>^#T-5**H\DZBO%*WH_3\"(3>(]I3HM1FY7TOJO)^NIM^)-(L]'\(3P6
M<956F1F9CEF.>YKFA=3ZF-*T:ZF^QV*JN&;H^?XOZ#L*WKR/5+OP.YO[B*9Y
M)5:-AG.W/0\5-/X>34_!=GDHMW;0;DD[$=U/M4U*;J2O35ERK3NK[%T:T:5-
M*J[OF:OO9VM<ZJRLK?3[2.UMHPD2# 'K[GU->5?'_P#Y%O2?^OMO_0#7<>$-
M1NKFT:SO"'D@ VR Y++V!]Q7(?'*PFO_  _IB0E 5NF)WDC^ ^@->OA)QGRR
MCHCPL93G"4HR=W^9H>/-2\)67A328_%%JUZ2J26UM%GS&95&3G(PO.#D]Z\T
M\9ZC8:IX9W6WP[N-&C1D\K4#%Y8 )Z'"C((XY-=?\4_#5W)I>B^*+.XB672H
M$#QR D'!#*1P03D=#U%<UJGB#Q3\1_!M]-<2Z=:Z?8O&9(HE<-.Y( R3G"C.
M?J!7532LF<DW=M&AXZTR?5?@_P"&/$&YFN[&&(22?Q;& &2?9@OYFCQCJ\GQ
M 3P1H=K+MEU",7-P<9V-@H21[;9#7HGA_14U/X3V6C76TK/IPA8CD E>#^!P
M:\Z^#/AJ:+Q9<W]Y)&YLK8QQ!6)PSM@GD<# ;_OJE&2LWVN-Q=TNY5\+>*9O
M#WPQ\7:/.WEWMA(8H5/4&4^6<?1@Q_&N_P#A-X:@T[X?V;W5NC37K-='>O(#
M8"C_ +Y5?SK@/B#X*DN?B@(;::..WU9X9) 6((+':QQCGH3]37OD$,=M!'!$
6H6*-0B*.P P!4U9+ETZZC@G?7H?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
